The outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 …

Coronavirus disease 2019 (COVID-19) has swept the world, unlike any other pandemic in
the last 50 years. Our understanding of the disease has evolved rapidly since the outbreak; …

Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …

Background The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global public health …

A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …

Hematoxylin and eosin-stained sections showed neither large areas of myocyte necrosis,
nor significant interstitial lymphocytic infiltrate (Figure B). The sections were remarkable for …

Platelets are chief cells in hemostasis. Apart from their hemostatic roles, platelets are major
inflammatory effector cells that can influence both innate and adaptive immune responses …

Dysregulated immune responses against the SARS-CoV-2 virus are instrumental in severe
COVID-19. However, the immune signatures associated with immunopathology are poorly …

Since the onset of the global pandemic in early 2020, coronavirus disease 2019 (COVID-19)
has posed a multitude of challenges to health care systems worldwide. In order to combat …

Ischaemia–reperfusion (I–R) injury, initiated via bursts of reactive oxygen species produced
during the reoxygenation phase following hypoxia, is well known in a variety of acute …